By continuing to browse the site, you are agreeing to our use of cookies. (More details)

M/F for Development and formulation of trastuzumab conjugates for imaging its brain delivery by intranasal adminstration

This offer is available in the following languages:
- Français-- Anglais

Application Deadline : 24 October 2024 23:59:00 Paris time

Ensure that your candidate profile is correct before applying.

General information

Offer title : M/F for Development and formulation of trastuzumab conjugates for imaging its brain delivery by intranasal adminstration (H/F)
Reference : UMR6302-CLALEJ-008
Number of position : 1
Workplace : DIJON
Date of publication : 03 October 2024
Type of Contract : PhD Student contract / Thesis offer
Contract Period : 36 months
Start date of the thesis : 4 November 2024
Proportion of work : Full time
Remuneration : 2 135,00 € gross monthly
Section(s) CN : Chemistry of and for life: design and properties of molecules of biological interest

Description of the thesis topic

The objective of the thesis is the synthesis and formulation of trastuzumab conjugates (full antibody and Fab fragments). The antibodies will be conjugated to DFO (a 89Zr chelating agent for PET imaging) and to a fluorophore (IRDye 800CW). The formulation with PLGA and the radiolabeling with 89Zr will be performed and the distribution of the conjugates using two administration routes (nasal vs intravenous) will be followed by imaging. The thesis is part of the ANR PRCE Nose To Brain N2B project, coordinated by Dr. Didier Boquet from the Joliot Institute (CEA).

Work Context

The thesis will be carried out within the Institute of Molecular Chemistry of the University of Burgundy (UMR CNRS 6302), in the RITM team (Radiopharmaceuticals, Imaging, Theranostics and Multimodality) of the ISI Department (Engineering, Health and Imaging) under the joint supervision of Prof. Franck Denat, chemist, and Dr. Bertrand Collin, MCU PH radiopharmacist and head of the “Imathera” preclinical imaging and radiotherapy platform (BioSanD - UMS INSERM 58). The thesis will be carried out within the framework of a strong partnership with the Cancer Center Georges-François Leclerc (CGFL) where the “Imathera” platform is located. The CGFL is a partner of the ANR N2B with the ICMUB, the Joliot Institute (CEA) and the company CERES Brain Therapeutics.
The PhD student will depend on the CARNOT-PASTEUR doctoral school, which brings together PhD students in physics, chemistry and mathematics from the University of Burgundy and the University of Franche-Comté.

The position is located in a sector under the protection of scientific and technical potential (PPST), and therefore requires, in accordance with the regulations, that your arrival is authorized by the competent authority of the MESR.

Constraints and risks

The PhD student will work both in the ICMUB lab and on the two sites of the “Imathera” platform, especially for handling radioactive products, in the respect of the rules of these two labs. Access to the ICMUB, classified as ZRR (restricted area), will be subject to the authorization from the French authorities.